How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 965-973

  Tafuri, Giovanni ^a,b   Pagnini, Margherita ^a   Moseley, Jane ^a   Massari, Marco ^b   Petavy, Frank ^a   Behring, Antje ^c   Catalan, Arantxa ^d   Gajraj, Elangovan ^e   Hedberg, Niklas ^f   Obach, Mercè ^d   Osipenko, Leeza ^e   Russo, Pierluigi ^b   Van De Casteele, Marc ^g   Zebedin, Eva Maria ^h   Rasi, Guido ^a   Vamvakas, Spiros ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b ITALIAN MEDICINES AGENCY   (Italy)

^c Joint Committee (G BA)   (Germany)

^d Catalan Agency for Health Information Assessment and Quality (CAHIAQ)   (Spain)

^e NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^f The Dental and Pharmaceutical Benefits Agency (TLV)   (Sweden)

^g National Institute for Sickness and Invalidity Insurance (INAMI)   (Belgium)

^h Main Assoc of Austrian Social Security Institutions   (Austria)

Author keywords

agreement; EMA; Health Technology Assessment; parallel scientific advice; regulatory

Indexed keywords

ARTICLE; CLINICAL STUDY; COMPARATIVE STUDY; DRUG SCREENING; EUROPEAN MEDICINES AGENCY; EUROPEAN UNION; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; POPULATION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY CONTROL; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; STUDY DESIGN;

EID: 84986275928     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13023     Document Type: Article

References (20)

1. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008; 24: 244–58.
2. Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov 2010; 9: 277–91.
3. van Nooten F, Holmstrom S, Green J, Wiklund I, Odeyemi IA, Wilcox TK. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. Drug Discov Today 2012; 17: 615–22.
4. Ciani O, Jommi C. The role of health technology assessment bodies in shaping drug development. Drug Des Devel Ther 2014; 8: 2273–81.
5. Pharmaceutical industry: a strategic sector for the European economy. European Commission, Brussels, 1.8.2014 SWD(2014) 216 final/2. Available at http://ec.europa.eu/growth/sectors/healthcare/index_en.htm (last accessed March 2016)
6. Russo P, Mennini FS, Siviero PD, Rasi G. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol 2010; 21: 2081–7.
7. Scientific advice and protocol assistance. Available at http://www.ema.europa.eu/ema/index.jsp%3Fcurl%3Dpages/regulation/general/general_content_000049.jsp%26mid%3DWC0b01ac05800229b9 (last accessed March 2016)
8. Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available, EMA/759784/2010. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/01/WC500100710.pdf (last accessed March 2016)
9. Call for Expression of Interest for health care product developers - SEED (Shaping European Early Dialogues). EUnetHTA website. Available at http://www.eunethta.eu/news/call-expression-interest-health-care-product-developers-seed-shaping-european-early-dialogues (last accessed March 2016)
10. Best practice guidance for pilot EMA HTA parallel scientific advice procedures. EMA/109608/2014. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/05/WC500166226.pdf (last accessed March 2016)
11. Grepstad M, Kanavos P. A comparative analysis of coverage decisions for outpatient pharmaceuticals: evidence from Denmark, Norway and Sweden. Health Policy 2015; 119: 203–11.
12. Nicod E, Kanavos P. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy 2012; 108: 167–77.
13. Mathes T, Jacobs E, Morfeld JC, Pieper D. Methods of international health technology assessment agencies for economic evaluations – a comparative analysis. BMC Health Serv Res 2013; 13: 371.
14. Towards a harmonised EU assessment of the added therapeutic value of medicines. Study for the ENVI Committee, European Parliament, 2015. Available at http://www.europarl.europa.eu/RegData/etudes/STUD/2015/542219/IPOL_STU(2015)542219_EN.pdf (last accessed March 2016)
15. EUnetHTA website, available at http://www.eunethta.eu/ (last accessed March 2016)
16. Berntgen M, Gourvil A, Pavlovic M, Goettsch W, Eichler HG, Kristensen FB. Improving the contribution of regulatory assessment reports to health technology assessments – a collaboration between the European Medicines Agency and the European network for Health Technology Assessment. Value Health 2014; 17: 634–41.
17. Health Technology Assessment Network, European Commission website. available at http://ec.europa.eu/health/technology_assessment/policy/network/index_en.htm (last accessed March 2016)
18. Reflection paper: EU Health Technology Assessment Network: strategy for EU cooperation on health technology assessment. Available at http://ec.europa.eu/health/technology_assessment/docs/2014_strategy_eucooperation_hta_en.pdf (last accessed March 2016)
19. Eichler HG1, Baird LG, Barker R, Bloechl-Daum B, Børlum-Kristensen F, Brown J. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 2015; 97: 234–46.
20. Qualification of novel methodologies for medicine development. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000319.jsp (last accessed March 2016)